Related Experiment Videos
Primary localized cutaneous nodular amyloidosis successfully treated with cyclophosphamide
Philip L Tong1, William A Walker, Ross J Glancy
1Sir Charles Gairdner Hospital, Hospital Avenue, Nedlands, WA 6009, Australia. philipleitong@gmail.com
The Australasian Journal of Dermatology
|February 5, 2013
Summary
Primary localized cutaneous nodular amyloidosis (PLCNA) is a rare skin condition. A patient with PLCNA and CREST syndrome responded well to cyclophosphamide, showing no new amyloid deposits and healing skin ulcers.
Area of Science:
- Dermatology
- Rheumatology
- Immunology
Background:
- Primary localized cutaneous nodular amyloidosis (PLCNA) is a rare condition.
- It is often associated with connective tissue disorders.
- Treatment options for PLCNA are limited and often ineffective.
Observation:
- A middle-aged woman with PLCNA, CREST syndrome, and Sjögren's syndrome was treated.
- Previous therapies for her condition had been unsuccessful.
- The patient had experienced skin ulceration for many years.
Findings:
- The patient responded positively to cyclophosphamide therapy.
- No new amyloid deposits were observed after treatment.
- Skin ulceration resolved, and no new lesions appeared over many years.
Implications:
- Cyclophosphamide may be an effective treatment for recalcitrant PLCNA.
- Patients with PLCNA require monitoring for progression to systemic amyloidosis.
- This case highlights a potential therapeutic option for a rare and difficult-to-treat condition.
